产品介绍
Product Description
Application
The pharmacodynamics profile of SB 222200 enables its use as a tool to study physiological and pathophysiological roles of NK-3 receptor in CNS-modulated behaviors.
Biochem/physiol Actions
Non-peptide NK3 tachykinin receptor antagonist.
SB 222200 is a 2-phenyl-4-quinolinecarboxamides and a selective, reversible and competitive antagonist of human NK-3 receptor that effectively crosses the blood-brain barrier. It inhibits the NK-3 receptor-induced miosis or pupil constriction in conscious rabbits.1,2
Features and Benefits
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from GlaxoSmithKline
技术参数
Specifications
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | solid |
| color | light yellow |
| solubility | DMSO: soluble ~28 mg/mL,H2O: insoluble |
| originator | GlaxoSmithKline |
| storage temp. | 2-8°C |
| SMILES string | CC[C@H](NC(=O)c1c(C)c(nc2ccccc12)-c3ccccc3)c4ccccc4 |
| InChI | 1S/C26H24N2O/c1-3-22(19-12-6-4-7-13-19)28-26(29)24-18(2)25(20-14-8-5-9-15-20)27-23-17-11-10-16-21(23)24/h4-17,22H,3H2,1-2H3,(H,28,29)/t22-/m0/s1 |
| InChI key | MQNYRKWJSMQECI-QFIPXVFZSA-N |
| Gene Information | human ... TACR2(6865), TACR3(6870) |
